References
- Sievert KD, Amend B, Nagele U et al. Economic aspects of bladder cancer: what are the benefits and costs? World J. Urol. DOI: 10.1007/s00345-009-0395-z (2009) (Epub ahead of print).
- American Cancer Society. Cancer Facts & Figures 2009. American Cancer Society, Atlanta, GA, USA (2009).
- Grossman HB, Stenzl A, Moyad MA et al. Bladder cancer: chemoprevention, complementary approaches and budgetary considerations. Scand. J. Urol. Nephrol. Suppl. (218), 213–233 (2008).
- Babjuk M, Oosterlinck W, Sylvester R et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur. Urol.54(2), 303–314 (2008).
- Oosterlinck W. Guidelines on diagnosis and treatment of superficial bladder cancer. Minerva Urol. Nefrol.56(1), 65–72 (2004).
- Stenzl A, Cowan NC, De Santis M et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur. Urol. DOI:10.1016/j.eururo.2009.01.002 (2009) (Epub ahead of print).
- Soloway MS, Murphy W, Rao MK et al. Serial multiple-site biopsies in patients with bladder cancer. J. Urol.120, 57–59 (1978).
- Jakse G, Algaba F, Malmstrom PU et al. A second-look TUR in T1 transitional cell carcinoma: why? Eur. Urol.45(5), 539–546 (2004).
- Krieg RC, Messmann H, Rauch J et al. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem. Photobiol.76(5), 518–525 (2002).
- Brausi M, Collette L, Kurth K et al. Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur. Urol.41(5), 523–531 (2002).
- Hungerhuber E, Stepp H, Kriegmair M et al. Seven years’ experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder. Urology69(2), 260–264 (2007).
- Denzinger S, Burger M, Walter B et al. Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study. Urology69(4), 675–679 (2007).
- Stenzl A, Jocham D, Jichlinski P et al. [Photodynamic diagnostics in the urinary tract. Consensus paper of the Working Group for Oncology of the German Society for Urology]. Urologe A47(8), 982–987 (2008).
- Stenzl AS, Roessler WR, Fradet YF et al. Hexvix® fluorescence cystoscopy improves detection and resection of papillary bladder cancer and reduces early recurrence: a multicentre, prospective, randomized study. Presented at: The 24th EAU Congress. Stockholm, Sweden, 18–20 March 2009.
- Jichlinski P, Guillou L, Karlsen SJ et al. Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer: a multicenter study. J. Urol.170(1), 226–229 (2003).
- Jocham D, Witjes F, Wagner S et al. Improved detection and treatment of bladder cancer using hexaminolevulinate imaging: a prospective, Phase III multicenter study. J. Urol.174(3), 862–866 (2005).
- Stenzl A, Hoeltl L, Bartsch G. Fluorescence assisted transurethral resection of bladder tumors: is it cost effective? Eur. Urol.39, 31 (2001).
- Burger M, Zaak D, Stief CG et al. Photodynamic diagnostics and noninvasive bladder cancer: is it cost-effective in long-term application? A Germany-based cost analysis. Eur. Urol.52(1), 142–147 (2007).